Cencora, Inc.
CORCencora, Inc. (COR), formerly known as McKesson Corporation, is a global health care company that distributes pharmaceuticals, healthcare products, and medical supplies. It provides supply chain management, technology solutions, and healthcare services to hospitals, pharmacies, and other healthcare providers. The company plays a key role in ensuring the efficient flow of essential medical products across the healthcare industry.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 1, 2025 | $0.60 | 2025-11-14 | 2025-11-14 |
| September 3, 2025 | $0.55 | 2025-08-15 | 2025-08-15 |
| June 2, 2025 | $0.55 | 2025-05-16 | 2025-05-16 |
| March 3, 2025 | $0.55 | 2025-02-14 | 2025-02-14 |
| November 29, 2024 | $0.55 | 2024-11-15 | 2024-11-15 |
Dividends Summary
- Consistent Payer: Cencora, Inc. has rewarded shareholders with 88 dividend payments over the past 21 years.
- Total Returned Value: Investors who held COR shares during this period received a total of $23.35 per share in dividend income.
- Latest Payout: The most recent dividend of $0.60/share was paid 53 days ago, on December 1, 2025.
- Yield & Schedule: COR currently pays dividends quarterly with an annual yield of 0.64%.
- Dividend Growth: Since 2004, the dividend payout has grown by 2300.0%, from $0.03 to $0.60.
- Dividend Reliability: COR has maintained or increased its dividend for 66 consecutive payments.
Company News
AOP Health US announced expanded distribution of Rapiblyk™ (landiolol), an FDA-approved ultra-short-acting beta-blocker for treating rapid heart rates in critical care settings. The drug is now available through four major pharmaceutical wholesalers: Cardinal, Cencora Specialty Distribution, McKesson Corporation, and Morris & Dickson, enhancing...
Cencora agreed to acquire a majority stake in OneOncology for $5 billion, funded through new debt financing. The transaction is expected to close by the end of fiscal 2026 second quarter and is anticipated to be earnings neutral in the first twelve months.
Iterum Therapeutics reports expanding market access for ORLYNVAH™, securing nearly 25% insurance coverage in the U.S. and signing a Medicare Part D rebate agreement with a top Pharmacy Benefit Manager, with potential coverage starting in Q1 2026.
Cencora reported strong Q3 financial results with sales increasing 8.7% to $80.66 billion, driven by growth in healthcare solutions and GLP-1 class product sales. The company raised its full-year adjusted EPS guidance and expects continued revenue growth.
The global cell and gene therapy third-party logistics market is projected to grow from $8.66 billion in 2024 to $20.98 billion by 2033, driven by technological advancements, increasing clinical studies, and personalized medicine demands.
